Ruxolitinib

ORLANDO — Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the American Academy of Dermatology Annual Meeting.

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following haploidentical hematopoietic stem cell transplantation, according to results of a single-arm study.

Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.

In this video, Tania Jain, MBBS, director of the Immune Effector Cell Therapy Program and associate professor of oncology at Johns Hopkins University, highlighted recent developments and available treatments in myeloproliferative neoplasms care.

Year-long ruxolitinib cream 1.5% treatment among children aged 2 to 11 years with extensive moderate to severe atopic dermatitis is safe, according to results presented at the Revolutionizing Atopic Dermatitis Conference.

Ruxolitinib cream 1.5% was safe and well tolerated up for the short- and long-term treatment of atopic dermatitis in adolescents, according to an analysis of two phase 3 studies.

Safety data for ruxolitinib cream, a Janus kinase inhibitor, in the first year after its approval has shown that the drug is generally well tolerated for the treatment of atopic dermatitis or vitiligo, according to a postmarketing review.

SAN DIEGO — Ruxolitinib cream improved quality of life outcomes, including sleep and itch, in children aged 2 to 11 years with atopic dermatitis, according to a poster presented at the American Academy of Dermatology Annual Meeting.

WASHINGTON — Ruxolitinib was efficacious and well tolerated in pediatric patients with mild to moderate atopic dermatitis, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Topical ruxolitinib cream significantly reduced skin manifestations caused by cutaneous graft-versus-host disease compared with vehicle cream, results from a randomized phase 2 study showed.